Taro Pharmaceutical Industries Ltd.
TARO
TARO was delisted on the 21st of June, 2024.
84 hedge funds and large institutions have $315M invested in Taro Pharmaceutical Industries Ltd. in 2020 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 26 increasing their positions, 34 reducing their positions, and 10 closing their positions.
12% more capital invested
Capital invested by funds: $283M → $315M (+$32.5M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
7% less funds holding
Funds holding: 90 → 84 (-6)
24% less repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 34
60% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 10
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $1.14M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Northern Trust
Chicago,
Illinois
|
+$4.66M |
| 2 |
BIP
Brandes Investment Partners
La Jolla,
California
|
+$4.58M |
| 3 |
Renaissance Technologies
New York
|
+$4.53M |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$2.86M |
| 5 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$2.43M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$6.99M |
| 2 |
APG Asset Management
Amsterdam,
Netherlands
|
-$3.35M |
| 3 |
JP Morgan Chase
New York
|
-$2.05M |
| 4 |
Norges Bank
Oslo,
Norway
|
-$1.66M |
| 5 |
CAM
Claret Asset Management
Montreal,
Quebec, Canada
|
-$1.16M |
TARO Hedge Fund Activity: Q2 2020 in Review
84 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in Taro Pharmaceutical Industries Ltd. (TARO) for Q2 2020, worth a combined $315M — up 12% from $283M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of TARO and 4 opened new positions — a net loss of 6 holders — while 34 trimmed existing stakes and 26 added.
The largest buyer was Northern Trust, adding an estimated $4.66M. The largest seller was Citadel Advisors, cutting an estimated $6.99M.
- 84 institutional investors held Taro Pharmaceutical Industries Ltd. (TARO) as of Q2 2020, down from 90 in Q1 2020.
- Funds reported $315M of Taro Pharmaceutical Industries Ltd. stock for Q2 2020, up 12% quarter-over-quarter.
- 4 funds opened new Taro Pharmaceutical Industries Ltd. positions in Q2 2020 and 10 closed out, a net change of -6 holders.
- The largest Taro Pharmaceutical Industries Ltd. buyer in Q2 2020 was Northern Trust, an estimated $4.66M added.
- The largest Taro Pharmaceutical Industries Ltd. seller in Q2 2020 was Citadel Advisors, an estimated $6.99M sold.
Based on aggregated 13F filings for Q2 2020.